SALL4 as an indicator for the diagnosis of hepatoid carcinoma of the ovary: A case report and literature review

Jiana Li; Xiaohua Wu

doi:10.1002/ccr3.7706

SALL4 as an indicator for the diagnosis of hepatoid carcinoma of the ovary: A case report and literature review

Clin Case Rep. 2023 Jul 30;11(8):e7706. doi: 10.1002/ccr3.7706. eCollection 2023 Aug.

Authors

Jiana Li^{1

2}, Xiaohua Wu^{1

2}

Affiliations

¹ Department of Oncology, Shanghai Medical College Fudan University Shanghai China.
² Department of Gynecologic Oncology Fudan University Shanghai Cancer Center Shanghai China.

Abstract

Key clinical message: Primary HCO is a rare, aggressive ovarian malignant tumor, morphologically resembling HCC. SALL4 can be adopted to differentiate HCO from HCC. The serum AFP and CA125 rather than HE4 can be employed as possible biomarkers to track treatment and monitor recurrence.

Abstract: We report a case of a postmenopausal woman presenting with lower abdominal pain and vaginal bleeding. She went through a maximal debulking surgery, and the pathological biopsy revealed hepatoid carcinoma of the ovary (HCO). Immunohistochemical assay demonstrates SALL4 as an indicator to differentiate HCO from hepatocellular carcinoma (HCC).

Keywords: HCO; SALL4; diagnosis; hepatoid carcinoma of the ovary; therapy.

Publication types

Case Reports